<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cellectis — News on 6ix</title>
<link>https://6ix.com/company/cellectis</link>
<description>Latest news and press releases for Cellectis on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 19 Mar 2026 23:21:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cellectis" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836168078dffbe2df13d288.webp</url>
<title>Cellectis</title>
<link>https://6ix.com/company/cellectis</link>
</image>
<item>
<title>Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update</title>
<link>https://6ix.com/company/cellectis/news/cellectis-reports-full-year-2025-financial-results-and-provides-a-business-update-1</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/cellectis-reports-full-year-2025-financial-results-and-provides-a-business-update-1</guid>
<pubDate>Thu, 19 Mar 2026 23:21:00 GMT</pubDate>
<description>Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 populationIn target Phase 2 population: 100% of patients became eligible to transplantPivotal Phase 2 first interim analysis expected in Q4 2026BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) ongoing Best-in-class dual allogeneic CAR-T cell product targeting CD20 & CD22At current dose level, 88% ORR; 63% CR rate after 2+ prior line</description>
</item>
<item>
<title>Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026</title>
<link>https://6ix.com/company/cellectis/news/cellectis-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-19-2026</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/cellectis-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-19-2026</guid>
<pubDate>Thu, 12 Mar 2026 20:30:00 GMT</pubDate>
<description>NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2025 ending December 31, 2025 on Thursday, March 19, 2026 after the close of the US market. The publication will be followed by an investor conference call and webcast</description>
</item>
<item>
<title>Monthly information on share capital and company voting rights</title>
<link>https://6ix.com/company/cellectis/news/monthly-information-share-capital-company-213000631</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/monthly-information-share-capital-company-213000631</guid>
<pubDate>Wed, 04 Feb 2026 21:30:00 GMT</pubDate>
<description>(Article 223-16 of General Regulation of the French financial markets authority)PARIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights01/31/2026100,590,994105,825,481 For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, [email protected] Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 4</description>
</item>
<item>
<title>Cellectis Announces 2026 Strategy and Catalysts</title>
<link>https://6ix.com/company/cellectis/news/cellectis-announces-2026-strategy-catalysts-213000716</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/cellectis-announces-2026-strategy-catalysts-213000716</guid>
<pubDate>Thu, 08 Jan 2026 21:30:00 GMT</pubDate>
<description>NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today outlined its strategic priorities and key catalysts expected for 2026. “2025 was a transformational year for Cellectis, as we transitioned to a late-stage development allogeneic CAR-T company with the initiation of a pivotal Phase 2 trial for lasme-cel.</description>
</item>
<item>
<title>Cellectis Announces Arbitral Decision in Dispute with Servier</title>
<link>https://6ix.com/company/cellectis/news/cellectis-announces-arbitral-decision-dispute-215100534</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/cellectis-announces-arbitral-decision-dispute-215100534</guid>
<pubDate>Mon, 15 Dec 2025 21:51:00 GMT</pubDate>
<description>NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces that the Arbitral Tribunal has issued its decision in the arbitration proceedings against Les Laboratoires Servier and Institut de Recherches Internationales Servier IRIS SARL (“Servier”), relating to the License, Development and Commercialization A</description>
</item>
<item>
<title>ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL</title>
<link>https://6ix.com/company/cellectis/news/ash-2025-cellectis-presents-development-063000914</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/ash-2025-cellectis-presents-development-063000914</guid>
<pubDate>Mon, 08 Dec 2025 06:30:00 GMT</pubDate>
<description>Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapyIn vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion and persistenceIL-2 cohort enrollment to start in Q1 2026; full Phase 1 dataset expected in 2026 NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop</description>
</item>
<item>
<title>Moligo Technologies and Cellectis Demonstrate Potential of Enzymatic Single-Stranded DNA for Non-Viral Gene Editing in Nature Communications</title>
<link>https://6ix.com/company/cellectis/news/moligo-technologies-and-cellectis-demonstrate-potential-of-enzymatic-single-stranded-dna-for-non-viral-gene-editing-in-nature-communications</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/moligo-technologies-and-cellectis-demonstrate-potential-of-enzymatic-single-stranded-dna-for-non-viral-gene-editing-in-nature-communications</guid>
<pubDate>Fri, 21 Nov 2025 12:30:00 GMT</pubDate>
<description>Moligo Technologies, a DNA synthesis company advancing gene therapies, announced today the publication of an article in Nature Communications that demonstrates enzymatically synthesized single-stranded DNA (ssDNA) as a highly efficient non-viral donor template for gene insertion in hematopoietic stem and progenitor cells (HSPCs). The study, co-authored by Moligo and Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene t</description>
</item>
<item>
<title>Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells</title>
<link>https://6ix.com/company/cellectis/news/cellectis-publishes-nature-communications-article-111800301</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/cellectis-publishes-nature-communications-article-111800301</guid>
<pubDate>Wed, 19 Nov 2025 11:18:00 GMT</pubDate>
<description>NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today publishes an article in Nature Communications establishing circular single-stranded DNA (CssDNA) as a highly efficient non-viral DNA donor template, for gene insertion in hematopoietic stem and progenitor cells (HSPCs). Gene editing of HSPCs offers the</description>
</item>
<item>
<title>Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/cellectis/news/cellectis-reports-third-quarter-2025-213000998</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/cellectis-reports-third-quarter-2025-213000998</guid>
<pubDate>Fri, 07 Nov 2025 21:30:00 GMT</pubDate>
<description>Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9)Median OS of 14.8 months in patients who achieved MRD-negative CR/CRi First interim analysis for the BALLI-01 trial expected in Q4 2026 Eti-cel in r/r NHL (NATHALI-01) ORR of 86% and 57% CR rate (n=7)Development update to</description>
</item>
<item>
<title>Cellectis to Present a Development Update for eti-cel at ASH 2025</title>
<link>https://6ix.com/company/cellectis/news/cellectis-present-development-eti-cel-141500760</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/cellectis-present-development-eti-cel-141500760</guid>
<pubDate>Mon, 03 Nov 2025 14:15:00 GMT</pubDate>
<description>Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes in r/r NHLPreclinical data demonstrated that combining eti-cel with low-dose IL-2 may deepen and extend anti-tumor activity in patients with r/r NHLEti-cel full Phase 1 dataset, including low-dose IL-2 combination cohorts, expected to be presented in 2026Correlation between alemtuzumab exposure and response with lasme-cel (UCART22) allows optimization</description>
</item>
<item>
<title>Cellectis to Report Third Quarter Financial Results on November 7, 2025</title>
<link>https://6ix.com/company/cellectis/news/cellectis-report-third-quarter-financial-203000504</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/cellectis-report-third-quarter-financial-203000504</guid>
<pubDate>Fri, 31 Oct 2025 20:30:00 GMT</pubDate>
<description>NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2025 ending September 30, 2025 on Friday, November 7, 2025 after the close of the US market. The press release will be available in the Investors section of Cellectis’ website: https:/</description>
</item>
<item>
<title>Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL</title>
<link>https://6ix.com/company/cellectis/news/cellectis-r-d-day-highlights-191900251</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/cellectis-r-d-day-highlights-191900251</guid>
<pubDate>Thu, 16 Oct 2025 19:19:00 GMT</pubDate>
<description>○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) ○ Safety: in Phase 1 (n=40), lasme-cel was generally well-tolerated (including 1 case of grade 2 IEC-HS which resolved) ○ Durability: in patients who achieved MRD-negative CR/CRi, median OS was 14.8 months ○ In the target Phase 2 population, CR/CRi rate of 56% with ~80% of patients achieving MRD-negative status ○ In the target Phase 2 population, 100% patients became transpl</description>
</item>
<item>
<title>Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers</title>
<link>https://6ix.com/company/cellectis/news/cellectis-hosts-r-d-day-110000934</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/cellectis-hosts-r-d-day-110000934</guid>
<pubDate>Thu, 16 Oct 2025 11:00:00 GMT</pubDate>
<description>Event features full Phase 1 data and pivotal Phase 2 strategy for lasme-cel (UCART22) in r/r B-ALL NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today hosts a R&D Day in New York City. The Company’s leadership team and key opinion leaders will present the full Phase 1 dataset and outline the pivotal Phas</description>
</item>
<item>
<title>Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress</title>
<link>https://6ix.com/company/cellectis/news/cellectis-present-data-non-viral-064000593</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/cellectis-present-data-non-viral-064000593</guid>
<pubDate>Tue, 07 Oct 2025 06:40:00 GMT</pubDate>
<description>NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that findings highlighting the strong potential of circular single-stranded DNA (CssDNA) as a universal, efficient non-viral template for gene therapy, along with a comprehensive study of TALE base editors (TALEB) off-targets in the nuclear ge</description>
</item>
<item>
<title>Factor Bioscience Files Complaint Against Cellectis and AstraZeneca Alleging Infringement of Foundational Gene-Editing Patents</title>
<link>https://6ix.com/company/cellectis/news/factor-bioscience-files-complaint-against-cellectis-and-astrazeneca-alleging-infringement-of-foundational-gene-editing-patents</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/factor-bioscience-files-complaint-against-cellectis-and-astrazeneca-alleging-infringement-of-foundational-gene-editing-patents</guid>
<pubDate>Fri, 26 Sep 2025 15:00:00 GMT</pubDate>
<description>Factor Bioscience Inc. (Factor), a Cambridge, Massachusetts-based biotechnology company focused on using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced a complaint filed against Cellectis Inc., Cellectis SA, AstraZeneca PLC, AstraZeneca Ireland Limited, and AstraZeneca Holdings B.V.</description>
</item>
<item>
<title>Cellectis Reports Second Quarter 2025 Financial Results & Business Updates</title>
<link>https://6ix.com/company/cellectis/news/cellectis-reports-second-quarter-2025-203000766</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/cellectis-reports-second-quarter-2025-203000766</guid>
<pubDate>Mon, 04 Aug 2025 20:30:00 GMT</pubDate>
<description>Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented End-of-Phase 1 meetings with FDA & EMA for lasme-cel (UCART22) in r/r B-ALL completed in July 2025; on track to launch pivotal Phase 2 in H2 2025 Servier arbitration: arbitral decision expected to be rendered on or before December 15, 2025 eti-cel (UCART20x22): Phase 1 study in r/r NHL ongoing with readout expected in</description>
</item>
<item>
<title>Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025</title>
<link>https://6ix.com/company/cellectis/news/cellectis-report-second-quarter-2025-203000041</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/cellectis-report-second-quarter-2025-203000041</guid>
<pubDate>Mon, 28 Jul 2025 20:30:00 GMT</pubDate>
<description>NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2025 ending June 30, 2025 on Monday August 4, 2025 after the close of the US market. The publication will be followed by an investor conference call and webcast on Tuesday August 5, 2</description>
</item>
<item>
<title>Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025</title>
<link>https://6ix.com/company/cellectis/news/cellectis-reports-results-shareholders-meeting-203000379</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/cellectis-reports-results-shareholders-meeting-203000379</guid>
<pubDate>Thu, 26 Jun 2025 20:30:00 GMT</pubDate>
<description>NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, during which approximately 57% of voting rights were exercised, resolutions 1 through 23 and resolutions 25 and 26 were adopted,</description>
</item>
<item>
<title>Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025</title>
<link>https://6ix.com/company/cellectis/news/cellectis-annual-shareholders-general-meeting-203000376</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/cellectis-annual-shareholders-general-meeting-203000376</guid>
<pubDate>Wed, 21 May 2025 20:30:00 GMT</pubDate>
<description>NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 26, 2025 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The notice convening the annual general meeting stating the detailed agenda and modalities of</description>
</item>
<item>
<title>Cellectis Reports Financial Results for the First Quarter 2025</title>
<link>https://6ix.com/company/cellectis/news/cellectis-reports-financial-results-first-203000437</link>
<guid isPermaLink="true">https://6ix.com/company/cellectis/news/cellectis-reports-financial-results-first-203000437</guid>
<pubDate>Mon, 12 May 2025 20:30:00 GMT</pubDate>
<description>Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025AstraZeneca partnership: R&D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderCellectis will present novel non-viral</description>
</item>
</channel>
</rss>